「生醫合成實驗室」，該研究團隊長期從事下列五項研究工作：一、藥物設計與合成；二、「核酸切割試劑」之發明；三、分子基因體學；四、生醫奈米材料之合成；及五、天然物合成。本實驗室於2011–2014 年間，將與21 個國際知名研究團隊合作，進行下述有關發展抑制新興與被忽略RNA 病毒之先導藥物之研究計畫。該計劃已被歐盟核准，四年共計經費1,200 萬歐元（約5 億1396 萬元台幣）。並於2010 年10 月14 日，各研究團隊之主持人群聚於德國「盧貝克」舉辦「啟動」會議，協商與分配工作項目，並促進團隊整合。每年有數以百萬計的人受到RNA 病毒之感染而死亡，其數量之龐大乃源於當前缺乏有效之疫苗與藥物。針對此一重大議題，本計劃聯合了歐亞之傑出病毒學家、生物學家、藥物化學家，與生物資訊學家，共同投入設計及開發新型藥物。共計有九個歐盟國及三個亞洲國家的科學家同心協力，激發出最先進的藥物發展及設計之計畫。本計劃簡稱 SILVER，其目的為發展抑制新興與被忽略之RNA 病毒之小分子先導藥物；重心為針對重要RNA 病毒，如登革熱、腸病毒，與副黏液病毒等，發展出具有抑制功能之藥物。此外也將研究並確定被忽略的RNA 病毒之蛋白質，並發展出有效先導藥物。此一國際團隊實力堅強，執行計畫之同時亦能促進國際間之合作，其成果能用於改善世界醫療之品質。 Professor Reuben Jih-Ru Hwu is in charge of the “Biomedical Synthesis Laboratory” on the campuses of National Tsing Hua University and National Central University. His research group has been carrying out long-term research projects in the following five fields: 1. Drug Design and Synthesis, 2. DNA-cleaving Agents, 3. Molecular Genomics, 4. Nano-biomaterials, and 5. Natural Product Synthesis. Within the four years between 2011–2014, this team will collaborate with 21 internationally renowed research groups in development of small-molecule inhibitor leads versus emerging and neglected RNA viruses. The European Commission has approved the financial support with a total budget of €12 million over the four-year period. In the kick-off meeting held at Lübeck, Germany on 14 October 2010, all of the consortium leaders worked together and decided the job distributions as well as the collaboration pattern. This consortium will work on RNA virus infections, which kill millions of humans annually. It is largely due to the lack of suitable vaccines and drugs to control them. This problem is addressed in the FP7 call and in response a consortium of Europe’s and Asia’s leading molecular virologists, structural biologists, medicinal chemists, and bioinformaticians. These scientists, coming from nine countries of Europe and three countries of Asia, have been brought together to generate a state-of-the-art drug discovery and design program. The project aims to identify Small molecule Inhibitor Leads Versus Emerging and neglected RNA viruses (SILVER). It will focus its activities on selected medically important RNA viruses, for which the development of drugs is considered essential. The dengue-, entero- and paramyxoviruses are among the top priority. Other relatively neglected and/or emerging RNA viruses will be also explored to identify the most promising viral protein targets and antiviral compounds. The SILVER consortium will be well placed to play a major role in contributing to the international effort to develop strategies to improve world health. 研究期間：10001 ~ 10012
